With a demonstrated track record of reaching milestones, building the concept , creating proof of value, succeed in early traction and initiating clinical studies, the team has proven its commitment to the strategy and the ability to execute. With the upcoming milestones of clinical studies, increased traction, progress in the regulatory process and evolvement in IP assets, the company expects a significant increase in value.

Investing in Brainsafe not only improves the lives of those affected but also makes a significant dent in healthcare costs. Be a part of the change and join us in revolutionizing concussion care.